Epidermal growth factor receptor (EGFR)-inhibitors, rashes, and survival: is doxycycline the missing link?
Palma
David
D
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects; D000068818:Cetuximab; D004318:Doxycycline / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000188:drug therapy* / Q000401:mortality; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans
D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D004318:Doxycycline; D000068818:Cetuximab